The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation

Harvey Pass, Dorothy Giroux, Catherine Kennedy, Enrico Ruffini, Ayten K Cangir, David Rice, Hisao Asamura, David Waller, John Edwards, Walter Weder, Hans Jürgen Hoffmann, Jan P van Meerbeeck, Anna Nowak, Valerie W Rusch, IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions

Research output: Contribution to journalArticle

Abstract

For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.

Original languageEnglish
Pages (from-to)2082-2088
Number of pages7
JournalJournal of Thoracic Oncology
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2016
Externally publishedYes

Fingerprint

Mesothelioma
Rare Diseases
Neoplasm Staging
Joints
Databases
Neoplasms
Public Opinion
Lymph Nodes
Clinical Trials
Malignant Mesothelioma

Keywords

  • Journal Article

Cite this

Pass, H., Giroux, D., Kennedy, C., Ruffini, E., Cangir, A. K., Rice, D., ... IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions (2016). The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. Journal of Thoracic Oncology, 11(12), 2082-2088. https://doi.org/10.1016/j.jtho.2016.09.123

The IASLC Mesothelioma Staging Project : Improving Staging of a Rare Disease Through International Participation. / Pass, Harvey; Giroux, Dorothy; Kennedy, Catherine; Ruffini, Enrico; Cangir, Ayten K; Rice, David; Asamura, Hisao; Waller, David; Edwards, John; Weder, Walter; Hoffmann, Hans Jürgen; van Meerbeeck, Jan P; Nowak, Anna; Rusch, Valerie W; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

In: Journal of Thoracic Oncology, Vol. 11, No. 12, 12.2016, p. 2082-2088.

Research output: Contribution to journalArticle

Pass, H, Giroux, D, Kennedy, C, Ruffini, E, Cangir, AK, Rice, D, Asamura, H, Waller, D, Edwards, J, Weder, W, Hoffmann, HJ, van Meerbeeck, JP, Nowak, A, Rusch, VW & IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions 2016, 'The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation', Journal of Thoracic Oncology, vol. 11, no. 12, pp. 2082-2088. https://doi.org/10.1016/j.jtho.2016.09.123
Pass, Harvey ; Giroux, Dorothy ; Kennedy, Catherine ; Ruffini, Enrico ; Cangir, Ayten K ; Rice, David ; Asamura, Hisao ; Waller, David ; Edwards, John ; Weder, Walter ; Hoffmann, Hans Jürgen ; van Meerbeeck, Jan P ; Nowak, Anna ; Rusch, Valerie W ; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. / The IASLC Mesothelioma Staging Project : Improving Staging of a Rare Disease Through International Participation. In: Journal of Thoracic Oncology. 2016 ; Vol. 11, No. 12. pp. 2082-2088.
@article{b0e3fc61f78246da9c63ea309dd2f71d,
title = "The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation",
abstract = "For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.",
keywords = "Journal Article",
author = "Harvey Pass and Dorothy Giroux and Catherine Kennedy and Enrico Ruffini and Cangir, {Ayten K} and David Rice and Hisao Asamura and David Waller and John Edwards and Walter Weder and Hoffmann, {Hans J{\"u}rgen} and {van Meerbeeck}, {Jan P} and Anna Nowak and Rusch, {Valerie W} and {IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions}",
note = "Copyright {\circledC} 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = "12",
doi = "10.1016/j.jtho.2016.09.123",
language = "English",
volume = "11",
pages = "2082--2088",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - The IASLC Mesothelioma Staging Project

T2 - Improving Staging of a Rare Disease Through International Participation

AU - Pass, Harvey

AU - Giroux, Dorothy

AU - Kennedy, Catherine

AU - Ruffini, Enrico

AU - Cangir, Ayten K

AU - Rice, David

AU - Asamura, Hisao

AU - Waller, David

AU - Edwards, John

AU - Weder, Walter

AU - Hoffmann, Hans Jürgen

AU - van Meerbeeck, Jan P

AU - Nowak, Anna

AU - Rusch, Valerie W

AU - IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions

N1 - Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

PY - 2016/12

Y1 - 2016/12

N2 - For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.

AB - For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.

KW - Journal Article

U2 - 10.1016/j.jtho.2016.09.123

DO - 10.1016/j.jtho.2016.09.123

M3 - Article

C2 - 27670823

VL - 11

SP - 2082

EP - 2088

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 12

ER -